Artivion Slashes 2026 Outlook After Q1 Beat, Citing NEXUS Product Delay
summarizeSummary
Artivion reported first-quarter results that slightly beat analyst expectations for revenue and adjusted EPS. However, the company significantly lowered its full-year 2026 revenue guidance from $486M-$504M to $480M-$496M, and adjusted EBITDA guidance from $105M-$110M to $100M-$107M. This downward revision is primarily attributed to U.S. revenue from its NEXUS product sales being negligible in 2026, ahead of a planned 2027 launch. While Q1 performance showed growth in stent grafts and On-X products, the reduced outlook for the full year is a material negative development for investors, indicating a slower growth trajectory than previously anticipated and likely impacting future valuation. Traders will be watching for further updates on the NEXUS product launch and any additional commentary on "transient factors" affecting Q1.
At the time of this announcement, AORT was trading at $24.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $26.84 to $48.25. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.